Gut microbiota-driven drug metabolism in inflammatory bowel disease
- PMID: 32652007
- PMCID: PMC7904070
- DOI: 10.1093/ecco-jcc/jjaa143
Gut microbiota-driven drug metabolism in inflammatory bowel disease
Abstract
Background and aims: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature about microbial drug metabolism of medication prescribed in inflammatory bowel disease practice.
Methods: A systematic literature search was performed in Embase and PubMed from inception to October 2019. The search was conducted with predefined MeSH/Emtree and text terms. All studies about drug metabolism by microbiota of medication prescribed in inflammatory bowel disease practice were eligible. A total of 1018 records were encountered and 89 articles were selected for full text reading.
Results: Intestinal bacterial metabolism or modulation is of influence in four specific drugs used in inflammatory bowel disease (mesalazines, methotrexate, glucocorticoids and thioguanine). The gut microbiota cleaves the azo-bond of sulfasalazine, balsalazide and olsalazine and releases the active moiety 5-aminosalicylic acid. It has an impact on the metabolization and potentially on the response of methotrexate therapy. Especially thioguanine can be converted by intestinal bacteria into the pharmacological active 6-thioguanine nucleotides without the requirement of host metabolism. Glucocorticoid compounds can be prone to bacterial degradation.
Conclusion: The human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in inflammatory bowel disease practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new inflammatory bowel disease medication.
Keywords: Drug Metabolism; Inflammatory bowel disease; Microbiota.
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Figures
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843. JBI Database System Rev Implement Rep. 2016. PMID: 27532314
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Stem cell transplantation for induction of remission in medically refractory Crohn's disease.Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2. Cochrane Database Syst Rev. 2022. PMID: 35556242 Free PMC article.
Cited by
-
Pulchinenoside B4 ameliorates oral ulcers in rats by modulating gut microbiota and metabolites.Appl Microbiol Biotechnol. 2024 Apr 9;108(1):292. doi: 10.1007/s00253-024-13099-1. Appl Microbiol Biotechnol. 2024. PMID: 38592514 Free PMC article.
-
Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era.Biomedicines. 2024 Jan 16;12(1):194. doi: 10.3390/biomedicines12010194. Biomedicines. 2024. PMID: 38255298 Free PMC article. Review.
-
Causal Effects of Gut Microbiome on Systemic Lupus Erythematosus: A Two-Sample Mendelian Randomization Study.Front Immunol. 2021 Sep 7;12:667097. doi: 10.3389/fimmu.2021.667097. eCollection 2021. Front Immunol. 2021. PMID: 34557183 Free PMC article.
-
Application of artificial intelligence approaches to predict the metabolism of xenobiotic molecules by human gut microbiome.Front Microbiol. 2023 Dec 5;14:1254073. doi: 10.3389/fmicb.2023.1254073. eCollection 2023. Front Microbiol. 2023. PMID: 38116528 Free PMC article. Review.
-
Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis.Front Immunol. 2021 Oct 6;12:741934. doi: 10.3389/fimmu.2021.741934. eCollection 2021. Front Immunol. 2021. PMID: 34691046 Free PMC article.
References
-
- Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microb Pathog 2019;137:103774. - PubMed
-
- Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008;363:1–25. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources